Elicera Therapeutics Targets iTANK Patent in US After Latest Obstacle

Elicera Therapeutics, a Sweden-based clinical-stage immuno-oncology company, is developing next-generation cell and gene therapies for immune-based cancer treatment. The company is focusing on its iTANK platform patent in the US after overcoming the latest hurdle. Elicera has four drug candidates in development, including oncolytic viruses and CAR T-cell treatments, and has received support from the Swedish Cancer Society for a clinical phase I/II study of ELC-301, a CAR T-cell therapy for B-cell lymphoma.

Elicera Therapeutics AB (publ), a Sweden-based clinical-stage immuno-oncology company, has provided an update on the status of its iTANK platform patent application in the United States. The company, which specializes in next-generation cell and gene therapies for immune-based cancer treatment, has faced a setback in its patent application process but remains optimistic about its future prospects.

On August 25, 2025, Elicera Therapeutics announced that the ongoing patent application for the iTANK platform in the U.S. is still under examination by the United States Patent and Trademark Office (USPTO). The company’s patent attorney, Henrik Sjölander at Barker Brettell Sweden AB, commented on the recent decision by the Board of Appeals at the USPTO, which chose to uphold the examiner’s decision to reject the patent claims. Despite the rejection, Sjölander expressed confidence in the company's strategy to continue pursuing patent protection for the iTANK platform in the U.S.

The iTANK platform is a technology designed to enhance CAR T-cells by incorporating a transgene encoding a neutrophil activating bacterial protein (NAP). This technology aims to address two major challenges in the treatment of solid tumors: a diverse set of tumor antigen targets and a hostile tumor microenvironment. The platform has already been patented in Europe and China, where the respective patent offices have deemed the invention patentable.

Elicera Therapeutics has four drug candidates in development, including oncolytic viruses and CAR T-cell treatments. The company has received support from the Swedish Cancer Society for a clinical phase I/II study of ELC-301, a CAR T-cell therapy for B-cell lymphoma. The company's CEO, Jamal El-Mosleh, is optimistic that the USPTO will ultimately reach the same conclusion as the European and Chinese patent offices.

For further information, please contact Jamal El-Mosleh, CEO, Elicera Therapeutics AB (publ) at +46 (0) 703 31 90 51 or via email at jamal.elmosleh@elicera.com.